glp-1 receptor agonists adverse effects glp 1 agonist long term side Overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds Comparison of adverse effects between

Brand names: Ozempic (diabetes), Wegovy (obesity)

931 of 06-06-2022) - project n

Appendix Abbreviations AE(s): Adverse Event(s) BMI Body Mass Index CENTRAL Cochrane Central Register of Controlled Trials CI Confidence Interval CSF Cerebrospinal Fluid GLP-1 Glucagon-Like Peptide-1 GLP-1 RA(s) GLP-1 Receptor Agonist(s) I (Statistical measure of heterogeneity) ICP Intracranial Pressure IIH Idiopathic Intracranial Hypertension IQR Interquartile Ranges logMAR Logarithm of the Minimum Angle of Resolution MD Mean Difference NOS Newcastle-Ottawa Quality Assessment Scale PICO Population, Intervention, Comparison, and Outcomes PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses PROSPERO (International prospective register of systematic reviews Name, not an acronym defined in text) RCT(s) Randomized Controlled Trial(s) RoB2 Revised Cochrane risk-of-bias tool (for randomized trials) RR Risk Ratio SD Standard Deviation SMD Standardized Mean Difference ULN Upper Limit of Normal VRS Verbal Rating Scale WOS/WoS Web of Science Footnotes ORCID iDs: Jamal Ahmad Ahmed Mohamed Hamdy Bahaa Elfakharany Muhammad M

Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review

Carbonell C, Mathew Stephen M, Ruan Y, Warkentin MT, Brenner DR

Abbie Vie) and speaker fees (Heidelberg engineering